130 related articles for article (PubMed ID: 2520622)
1. Effects of cimetropium bromide on gastrointestinal transit time in patients with irritable bowel syndrome.
Passaretti S; Guslandi M; Imbimbo BP; Daniotti S; Tittobello A
Aliment Pharmacol Ther; 1989 Jun; 3(3):267-76. PubMed ID: 2520622
[TBL] [Abstract][Full Text] [Related]
2. Reduction by cimetropium bromide of the colonic motor response to eating in patients with the irritable bowel syndrome.
Lanfranchi GA; Bazzocchi G; Campieri M; Brignola C; Fois F; Imbimbo BP
Eur J Clin Pharmacol; 1988; 33(6):571-5. PubMed ID: 3366160
[TBL] [Abstract][Full Text] [Related]
3. Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome.
Centonze V; Imbimbo BP; Campanozzi F; Attolini E; Daniotti S; Albano O
Am J Gastroenterol; 1988 Nov; 83(11):1262-6. PubMed ID: 3055943
[TBL] [Abstract][Full Text] [Related]
4. Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial.
Dobrilla G; Imbimbo BP; Piazzi L; Bensi G
Gut; 1990 Mar; 31(3):355-8. PubMed ID: 2182401
[TBL] [Abstract][Full Text] [Related]
5. Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome.
Ferrari A; Cavallero M; Spandre M; Gemme C; Rossini FP; Imbimbo BP
Clin Ther; 1986; 8(3):320-8. PubMed ID: 3521859
[TBL] [Abstract][Full Text] [Related]
6. Effect of cimetropium bromide on esophageal motility and transit in patients affected by primary achalasia.
Marzio L; Grossi L; DeLaurentiis MF; Cennamo L; Lapenna D; Cuccurullo F
Dig Dis Sci; 1994 Jul; 39(7):1389-94. PubMed ID: 8026247
[TBL] [Abstract][Full Text] [Related]
7. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.
Houghton LA; Foster JM; Whorwell PJ
Aliment Pharmacol Ther; 2000 Jun; 14(6):775-82. PubMed ID: 10848662
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of caerulein-induced gall bladder emptying by cimetropium bromide in humans.
Gullo L; Scarpignato C; Casanova P; Corcioni E; Zappia L; Imbimbo BP
Eur J Clin Pharmacol; 1989; 37(5):483-6. PubMed ID: 2598986
[TBL] [Abstract][Full Text] [Related]
9. Cimetropium bromide in the treatment of crisis in infantile colic.
Savino F; Brondello C; Cresi F; Oggero R; Silvestro L
J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):417-9. PubMed ID: 11930101
[TBL] [Abstract][Full Text] [Related]
10. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome.
Gorard DA; Libby GW; Farthing MJ
Aliment Pharmacol Ther; 1994 Apr; 8(2):159-66. PubMed ID: 8038347
[TBL] [Abstract][Full Text] [Related]
11. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome.
Thumshirn M; Coulie B; Camilleri M; Zinsmeister AR; Burton DD; Van Dyke C
Aliment Pharmacol Ther; 2000 Jul; 14(7):869-78. PubMed ID: 10886042
[TBL] [Abstract][Full Text] [Related]
12. Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic perspectives.
Scarpignato C; Bianchi Porro G
Int J Clin Pharmacol Res; 1985; 5(6):467-77. PubMed ID: 3912339
[TBL] [Abstract][Full Text] [Related]
13. Different effects of atropine and cimetropium bromide on gastric emptying of liquids and antroduodenal motor activity in man.
Imbimbo BP; Gardino L; Palmas F; Frascio M; Canepa G; Scarpignato C
Hepatogastroenterology; 1990 Apr; 37(2):242-6. PubMed ID: 2341121
[TBL] [Abstract][Full Text] [Related]
14. Cimetropium bromide, a new antispasmodic agent, has no hemolytic effects in humans.
Piperno A; Muzio F; Imbimbo BP; Manoussakis S; Daniotti S; Fiorelli G
Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):464-7. PubMed ID: 3654034
[TBL] [Abstract][Full Text] [Related]
15. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome.
Lu CL; Chen CY; Chang FY; Chang SS; Kang LJ; Lu RH; Lee SD
J Gastroenterol Hepatol; 2000 Aug; 15(8):925-30. PubMed ID: 11022835
[TBL] [Abstract][Full Text] [Related]
16. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome.
Evangelista S
Curr Pharm Des; 2004; 10(28):3561-8. PubMed ID: 15579053
[TBL] [Abstract][Full Text] [Related]
17. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
[TBL] [Abstract][Full Text] [Related]
18. Abnormalities of GI transit in bloated irritable bowel syndrome: effect of bran on transit and symptoms.
Hebden JM; Blackshaw E; D'Amato M; Perkins AC; Spiller RC
Am J Gastroenterol; 2002 Sep; 97(9):2315-20. PubMed ID: 12358250
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome.
Kim HJ; Camilleri M; McKinzie S; Lempke MB; Burton DD; Thomforde GM; Zinsmeister AR
Aliment Pharmacol Ther; 2003 Apr; 17(7):895-904. PubMed ID: 12656692
[TBL] [Abstract][Full Text] [Related]
20. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.
Scarpignato C; Pelosini I
Can J Gastroenterol; 1999 Mar; 13 Suppl A():50A-65A. PubMed ID: 10202210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
